Nexus Pharmaceuticals Announces Launch of Tacrolimus Injection

We’re proud to share the news of our latest product launch: Tacrolimus Injection, USP 5 mg/mL, now available in a single-dose vial format. This critical immunosuppressant is indicated for the prevention of organ rejection in liver and kidney transplant patients, offering healthcare providers a new, cost-effective option in a convenient presentation.

This launch represents another step forward in our mission to make high-quality, hard-to-manufacture medications more accessible and efficient for real-world clinical use.

👉 Read the full press release here:
Nexus Pharmaceuticals Launches Tacrolimus Injection

Stay connected for more updates as we continue expanding our portfolio of life-saving solutions.

About Nexus Pharmaceuticals, LLC

Nexus Pharmaceuticals, LLC, a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality drug products fulfill a critical unmet medical need and deliver dependable life-saving treatment options when and where they’re needed most.